Lower your risk, increase your value.   Smart up your business and work with              !
Luc Villeneuve, PhD, CEO
Who We Are
Our Services
Customer Satisfaction

May 01, 2020

ImmunoSpot S6 FluoroCore analyzers

IMMUNI T acquired two new ImmunoSpot S6 FluoroCore analyzers (CTL Analysers, LLC), with 2-3 color Analyzers capable of performing both visible and fluorescent analyses to expand its capabilities in cell-based analysis.

The addition of these instruments provide more flexibility in performing cell-based assays and activated cell population quantification.

Moving forward, IMMUNI T offers multiplex analysis including the qualified and validated ELISPOT for regulated immune monitoring studies as well as bacterial, yeast, stem cell, tumor colony counting and other clonogenic assays.

October 22, 2019


Immuni T is proud to announce that we have been recognized by the Standards Council of Canada (SCC) as being compliant with the OECD Principles of Good Laboratory Practice (GLP). GLP regulates the conduct of all non-clinical safety studies worldwide; the SCC is the only monitoring body that grants GLP recognition in Canada.

GLP recognition means that Immuni T has the infrastructure, personnel, and knowledge to conduct studies that produce valid and high quality data intended for submission to Health Canada, the US FDA, and regulatory bodies around the world (IND or CTA). In the drug development process, these bodies use this data to decide whether clinical studies in humans can proceed.

Immuni T develops, validates, and executes GLP-compliant toxicity, anti-drug antibody (ADA), and other assays, to support non-clinical safety studies.

Immuni T is a Montreal-based contract research organization (CRO) that offers immunology services on flow cytometry, ligand binding, and cell-based platforms.

To learn more about Immuni T's GLP services, contact us at or +1-514-545-3097 extension 102.

November 07, 2018

Is Your Biotherapeutic Immunomodulatory? How to Use Immunoassays to Get the Right Answer

Topics covered in this webinar were:

  • Why assessment of immune-based therapies’ mechanism of action is pivotal to their further application

  • About the physiological relevance of ex vivo immuno-modulation assays and appropriate data interpretation

  • How having better knowledge of the immune characteristics of the drug at an early stage of development will save time and money and will allow better preclinical and clinical desig

1 / 5

Please reload


CRO services

BeLPT samples


5th floor, suite SB-5180

141 President-Kennedy Avenue , 

Montréal, Québec, Canada H2X-1Y4

P.O.BOX #3

Telephone : +1(514) 545 3097

Fax : +1(514) 545 3064



Telephone : +1(514) 545 3097 

Fax : +1(514) 545 3064

Email :